Spyre Therapeutics, Inc. SYRE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $97.19M+13.4% | $85.72M+32.1% | $64.9M-20.5% | $81.66M+68.4% | $48.49M-45.8% | ||
| $644.28M-4.0% | $670.81M+59.2% | $421.3M-5.3% | $444.92M-13.8% | $516.33M+0.5% | ||
| $763.95M-1.8% | $777.78M+54.1% | $504.6M-6.4% | $538.83M-5.4% | $569.77M-6.4% | ||
| $763.95M-1.8% | $777.78M+54.1% | $504.6M-6.4% | $538.83M-5.4% | $569.78M-6.4% | ||
| $85.16M+45.1% | $58.69M+26.8% | $46.27M-44.3% | $83.06M+17.5% | $70.68M+30.7% | ||
| $56.95M+113% | $26.68M-46.1% | $49.5M-40.4% | $83.06M-4.7% | $87.17M-3.9% | ||
| 400M0.0% | 400M0.0% | 400M0.0% | 400M0.0% | 400M+3,076,823% | ||
| -$1.2B-6.1% | -$1.13B-5.9% | -$1.07B-1.1% | -$1.05B-3.6% | -$1.02B-4.6% | ||
| $670.81M-6.2% | $715.24M+57.2% | $455.1M-0.1% | $455.77M-5.6% | $482.61M-6.8% | ||
| $763.95M-1.8% | $777.78M+54.1% | $504.6M-6.4% | $538.83M-5.4% | $569.78M-6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Spyre Therapeutics, Inc.'s total assets?
- Spyre Therapeutics, Inc. (SYRE) holds $764.0M in total assets, up 34.1% year over year.
- How much cash does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc. holds $97.2M in cash and equivalents.
- Can Spyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.97 — current assets exceed current liabilities.
- Where does Spyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.